Longitudinal transitions of exclusive and polytobacco electronic nicotine delivery systems (ENDS) use among youth, young adults and adults in the USA: findings from the PATH Study Waves 1-3 (2013-2016).
electronic nicotine delivery devices
non-cigarette tobacco products
prevention
surveillance and monitoring
Journal
Tobacco control
ISSN: 1468-3318
Titre abrégé: Tob Control
Pays: England
ID NLM: 9209612
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
16
12
2019
revised:
08
01
2020
accepted:
15
01
2020
entrez:
24
4
2020
pubmed:
24
4
2020
medline:
3
6
2021
Statut:
ppublish
Résumé
Electronic nicotine delivery systems (ENDS; including e-cigarettes) are rapidly evolving in the US marketplace. This study reports cross-sectional prevalence and longitudinal pathways of ENDS use across 3 years, among US youth (12-17 years), young adults (18-24 years) and adults 25+ (25 years and older). Data were from the first three waves (2013-2016) of the Population Assessment of Tobacco and Health Study, a nationally representative, longitudinal cohort study of US youth and adults. Respondents with data at all three waves (youth, n=11 046; young adults, n=6478; adults 25+, n=17 188) were included in longitudinal analyses. Weighted cross-sectional ever use of ENDS increased at each wave. Across all three waves, young adults had the highest percentages of past 12-month, past 30-day (P30D) and daily P30D ENDS use compared with youth and adults 25+. Only about a quarter of users had persistent P30D ENDS use at each wave. Most ENDS users were polytobacco users. Exclusive Wave 1 ENDS users had a higher proportion of subsequent discontinued any tobacco use compared with polytobacco ENDS users who also used cigarettes. ENDS use is most common among young adults compared with youth and adults 25+. However, continued use of ENDS over 2 years is not common for any age group. Health education efforts to reduce the appeal and availability of ENDS products might focus on reducing ENDS experimentation, and on reaching the smaller subgroups of daily ENDS users to better understand their reasons for use.
Identifiants
pubmed: 32321848
pii: tobaccocontrol-2019-055574
doi: 10.1136/tobaccocontrol-2019-055574
pmc: PMC7530834
mid: NIHMS1555848
doi:
Types de publication
Comparative Study
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
s147-s154Subventions
Organisme : NIDA NIH HHS
ID : HHSN271201100027C
Pays : United States
Informations de copyright
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: WMC reports long-term stock holdings in General Electric Company, 3M Company, and Pfizer Incorporated, unrelated to this manuscript. No financial disclosures were reported by the other authors of this paper.
Références
Clin Cancer Res. 2015 Feb 1;21(3):514-25
pubmed: 25573384
Tob Control. 2020 May;29(Suppl 3):s163-s169
pubmed: 32321850
Vital Health Stat 2. 1969 Jan;(31):1-24
pubmed: 5306564
Tob Control. 2019 Jan;28(1):115-116
pubmed: 29669749
Health Educ Behav. 2016 Jun;43(3):328-36
pubmed: 26304709
Ann Intern Med. 2017 Mar 21;166(6):390-400
pubmed: 28166548
Drug Alcohol Depend. 2019 Mar 1;196:9-13
pubmed: 30658221
Drug Alcohol Depend. 2018 Oct 1;191:279-285
pubmed: 30165328
Tob Control. 2020 May;29(Suppl 3):s139-s146
pubmed: 32321847
Nicotine Tob Res. 2017 Oct 1;19(10):1253-1254
pubmed: 28444309
Tob Control. 2020 May;29(Suppl 3):s216-s226
pubmed: 32321855
Tob Control. 2020 May;29(Suppl 3):s203-s215
pubmed: 32321854
Nicotine Tob Res. 2016 May;18(5):715-9
pubmed: 26525063
Nicotine Tob Res. 2018 Jul 9;20(8):1020-1024
pubmed: 29059443
MMWR Morb Mortal Wkly Rep. 2017 Jun 16;66(23):597-603
pubmed: 28617771
Tob Control. 2019 Nov;28(6):603-609
pubmed: 30377241
MMWR Morb Mortal Wkly Rep. 2015 Apr 17;64(14):381-5
pubmed: 25879896
Tob Control. 2020 May;29(Suppl 3):s155-s162
pubmed: 32321849
Nicotine Tob Res. 2019 Jan 1;21(1):14-24
pubmed: 29315420
Environ Health Perspect. 2018 Feb 21;126(2):027010
pubmed: 29467105
JAMA Netw Open. 2019 Feb 1;2(2):e187794
pubmed: 30707232
MMWR Morb Mortal Wkly Rep. 2018 Jan 19;67(2):53-59
pubmed: 29346338
PLoS One. 2013 Oct 24;8(10):e79332
pubmed: 24250756
Tob Control. 2015 Sep;24(5):442-8
pubmed: 24935441
MMWR Morb Mortal Wkly Rep. 2019 Feb 15;68(6):157-164
pubmed: 30763302
Am J Prev Med. 2017 Feb;52(2):e33-e66
pubmed: 27914771
MMWR Morb Mortal Wkly Rep. 2018 Jun 08;67(22):629-633
pubmed: 29879097
Tob Control. 2020 Mar;29(2):140-147
pubmed: 30760629
Tob Control. 2016 Sep;25(5):538-44
pubmed: 26357952
Nicotine Tob Res. 2014 Aug;16(8):1150-5
pubmed: 24847099
Pediatrics. 2014 Jul;134(1):e29-36
pubmed: 24918224
Tob Regul Sci. 2017 Apr;3(2 Suppl 1):S8-S16
pubmed: 28317004
Nicotine Tob Res. 2017 Nov 01;19(11):1345-1350
pubmed: 28013271
Tob Control. 2019 Nov;28(6):663-668
pubmed: 30297373
Tob Control. 2017 Jul;26(4):371-378
pubmed: 27507901
Nicotine Tob Res. 2017 Feb;19(2):160-167
pubmed: 27613896
Nicotine Tob Res. 2020 Apr 21;22(5):827-832
pubmed: 30371838
MMWR Morb Mortal Wkly Rep. 2016 Apr 15;65(14):361-7
pubmed: 27077789
Tob Control. 2019 Jan;28(1):50-59
pubmed: 29695458
J Adolesc Health. 2016 Dec;59(6):627-634
pubmed: 27720358
Tob Control. 2020 May;29(Suppl 3):s191-s202
pubmed: 32321853
Am J Prev Med. 2018 Nov;55(5):650-655
pubmed: 30219210
Pediatrics. 2015 Mar;135(3):409-15
pubmed: 25647680
Tob Control. 2020 May;29(Suppl 3):s178-s190
pubmed: 32321852
Am J Med. 2019 Aug;132(8):949-954.e2
pubmed: 30853474
N Engl J Med. 2017 Jan 26;376(4):342-353
pubmed: 28121512
Tob Control. 2020 May;29(Suppl 3):s170-s177
pubmed: 32321851
N Engl J Med. 2019 Jan 10;380(2):192-193
pubmed: 30554549
Tob Control. 2014 Jul;23 Suppl 3:iii3-9
pubmed: 24935895